[1]
Jansen GA, Ofman R, Ferdinandusse S, Ijlst L, Muijsers AO, Skjeldal OH, Stokke O, Jakobs C, Besley GT, Wraith JE, Wanders RJ. Refsum disease is caused by mutations in the phytanoyl-CoA hydroxylase gene. Nature genetics. 1997 Oct:17(2):190-3
[PubMed PMID: 9326940]
[2]
Braverman N, Chen L, Lin P, Obie C, Steel G, Douglas P, Chakraborty PK, Clarke JT, Boneh A, Moser A, Moser H, Valle D. Mutation analysis of PEX7 in 60 probands with rhizomelic chondrodysplasia punctata and functional correlations of genotype with phenotype. Human mutation. 2002 Oct:20(4):284-97
[PubMed PMID: 12325024]
[3]
Wanders RJ, Jansen GA, Skjeldal OH. Refsum disease, peroxisomes and phytanic acid oxidation: a review. Journal of neuropathology and experimental neurology. 2001 Nov:60(11):1021-31
[PubMed PMID: 11706932]
[4]
Van den Brink DM, Brites P, Haasjes J, Wierzbicki AS, Mitchell J, Lambert-Hamill M, de Belleroche J, Jansen GA, Waterham HR, Wanders RJ. Identification of PEX7 as the second gene involved in Refsum disease. Advances in experimental medicine and biology. 2003:544():69-70
[PubMed PMID: 14713215]
Level 3 (low-level) evidence
[5]
Jansen GA, van den Brink DM, Ofman R, Draghici O, Dacremont G, Wanders RJ. Identification of pristanal dehydrogenase activity in peroxisomes: conclusive evidence that the complete phytanic acid alpha-oxidation pathway is localized in peroxisomes. Biochemical and biophysical research communications. 2001 May 11:283(3):674-9
[PubMed PMID: 11341778]
[6]
Molzer B, Stöckler S, Bernheimer H. [Peroxisomal neurologic diseases and Refsum disease: very long chain fatty acids and phytanic acid as diagnostic markers]. Wiener klinische Wochenschrift. 1992:104(21):665-70
[PubMed PMID: 1282286]
[7]
Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, Steinberg SJ, Raymond GV, Braverman NE, Moser AB. Zellweger Spectrum Disorder. GeneReviews(®). 1993:():
[PubMed PMID: 20301621]
[8]
Wierzbicki AS, Lloyd MD, Schofield CJ, Feher MD, Gibberd FB. Refsum's disease: a peroxisomal disorder affecting phytanic acid alpha-oxidation. Journal of neurochemistry. 2002 Mar:80(5):727-35
[PubMed PMID: 11948235]
[9]
Claridge KG, Gibberd FB, Sidey MC. Refsum disease: the presentation and ophthalmic aspects of Refsum disease in a series of 23 patients. Eye (London, England). 1992:6 ( Pt 4)():371-5
[PubMed PMID: 1282471]
[10]
Warren M, Mierau G, Wartchow EP, Shimada H, Yano S. Histologic and ultrastructural features in early and advanced phases of Zellweger spectrum disorder (infantile Refsum disease). Ultrastructural pathology. 2018 May-Jun:42(3):220-227. doi: 10.1080/01913123.2018.1440272. Epub 2018 Feb 26
[PubMed PMID: 29482424]
[11]
Gibberd FB, Feher MD, Sidey MC, Wierzbicki AS. Smell testing: an additional tool for identification of adult Refsum's disease. Journal of neurology, neurosurgery, and psychiatry. 2004 Sep:75(9):1334-6
[PubMed PMID: 15314127]
[12]
Harari D, Gibberd FB, Dick JP, Sidey MC. Plasma exchange in the treatment of Refsum's disease (heredopathia atactica polyneuritiformis). Journal of neurology, neurosurgery, and psychiatry. 1991 Jul:54(7):614-7
[PubMed PMID: 1716665]
[13]
Bamiou DE, Spraggs PR, Gibberd FB, Sidey MC, Luxon LM. Hearing loss in adult Refsum's disease. Clinical otolaryngology and allied sciences. 2003 Jun:28(3):227-30
[PubMed PMID: 12755761]
[14]
Vandana VP, Bindu PS, Nagappa M, Sinha S, Taly AB. Audiological findings in Infantile Refsum disease. International journal of pediatric otorhinolaryngology. 2015 Aug:79(8):1366-9. doi: 10.1016/j.ijporl.2015.05.023. Epub 2015 May 30
[PubMed PMID: 26055198]
[15]
Hungerbühler JP, Meier C, Rousselle L, Quadri P, Bogousslavsky J. Refsum's disease: management by diet and plasmapheresis. European neurology. 1985:24(3):153-9
[PubMed PMID: 2581787]
[16]
Kohlschütter A, Santer R, Lukacs Z, Altenburg C, Kemper MJ, Rüther K. A child with night blindness: preventing serious symptoms of Refsum disease. Journal of child neurology. 2012 May:27(5):654-6. doi: 10.1177/0883073811424799. Epub 2011 Dec 7
[PubMed PMID: 22156782]
[17]
Mandel H, Meiron D, Schutgens RB, Wanders RJ, Berant M. Infantile refsum disease: gastrointestinal presentation of a peroxisomal disorder. Journal of pediatric gastroenterology and nutrition. 1992 Jan:14(1):83-5
[PubMed PMID: 1374125]
[18]
Horn MA, van den Brink DM, Wanders RJ, Duran M, Poll-The BT, Tallaksen CM, Stokke OH, Moser H, Skjeldal OH. Phenotype of adult Refsum disease due to a defect in peroxin 7. Neurology. 2007 Feb 27:68(9):698-700
[PubMed PMID: 17325280]
[19]
Plant GR, Hansell DM, Gibberd FB, Sidey MC. Skeletal abnormalities in Refsum's disease (heredopathia atactica polyneuritiformis). The British journal of radiology. 1990 Jul:63(751):537-41
[PubMed PMID: 1697202]
[20]
Klouwer FC, Huffnagel IC, Ferdinandusse S, Waterham HR, Wanders RJ, Engelen M, Poll-The BT. Clinical and Biochemical Pitfalls in the Diagnosis of Peroxisomal Disorders. Neuropediatrics. 2016 Aug:47(4):205-20. doi: 10.1055/s-0036-1582140. Epub 2016 Apr 18
[PubMed PMID: 27089543]
[21]
Wierzbicki AS, Sankaralingam A, Lumb PJ, Hardman TC, Sidey MC, Gibberd FB. Transport of phytanic acid on lipoproteins in Refsum disease. Journal of inherited metabolic disease. 1999 Feb:22(1):29-36
[PubMed PMID: 10070615]
[22]
Baldwin EJ, Gibberd FB, Harley C, Sidey MC, Feher MD, Wierzbicki AS. The effectiveness of long-term dietary therapy in the treatment of adult Refsum disease. Journal of neurology, neurosurgery, and psychiatry. 2010 Sep:81(9):954-7. doi: 10.1136/jnnp.2008.161059. Epub 2010 Jun 14
[PubMed PMID: 20547622]
[23]
Baldwin EJ, Harrington DJ, Sampson B, Feher MD, Wierzbicki AS. Safety of long-term restrictive diets for peroxisomal disorders: vitamin and trace element status of patients treated for Adult Refsum Disease. International journal of clinical practice. 2016 Mar:70(3):229-35. doi: 10.1111/ijcp.12770. Epub 2016 Jan 22
[PubMed PMID: 26799636]
[25]
Dubot P, Astudillo L, Touati G, Baruteau J, Broué P, Roche S, Sabourdy F, Levade T. Pregnancy outcome in Refsum disease: Affected fetuses and children born to an affected mother. JIMD reports. 2019 Mar:46(1):11-15. doi: 10.1002/jmd2.12020. Epub 2019 Mar 14
[PubMed PMID: 31240149]
[26]
Stepien KM, Wierzbicki AS, Poll-The BT, Waterham HR, Hendriksz CJ. The Challenges of a Successful Pregnancy in a Patient with Adult Refsum's Disease due to Phytanoyl-CoA Hydroxylase Deficiency. JIMD reports. 2017:33():49-53. doi: 10.1007/8904_2016_569. Epub 2016 Aug 13
[PubMed PMID: 27518778]
[27]
Lundberg A, Lilja LG, Lundberg PO, Try K. Heredopathia atactica polyneuritiformis (Refsum's disease). Experiences of dietary treatment and plasmapheresis. European neurology. 1972:8(6):309-24
[PubMed PMID: 4117669]
[28]
Gibberd FB, Billimoria JD, Page NG, Retsas S. Heredopathia atactica polyneuritiformis (refsum's disease) treated by diet and plasma-exchange. Lancet (London, England). 1979 Mar 17:1(8116):575-8
[PubMed PMID: 85164]
[29]
Sá MJ, Rocha JC, Almeida MF, Carmona C, Martins E, Miranda V, Coutinho M, Ferreira R, Pacheco S, Laranjeira F, Ribeiro I, Fortuna AM, Lacerda L. Infantile Refsum Disease: Influence of Dietary Treatment on Plasma Phytanic Acid Levels. JIMD reports. 2016:26():53-60. doi: 10.1007/8904_2015_487. Epub 2015 Aug 25
[PubMed PMID: 26303611]
[30]
Powers JM, Kenjarski TP, Moser AB, Moser HW. Cerebellar atrophy in chronic rhizomelic chondrodysplasia punctata: a potential role for phytanic acid and calcium in the death of its Purkinje cells. Acta neuropathologica. 1999 Aug:98(2):129-34
[PubMed PMID: 10442551]
[31]
Steinberg D, Vroom FQ, Engel WK, Cammermeyer J, Mize CE, Avigan J. Refsum's disease--a recently characterized lipidosis involving the nervous system. Combined clinical staff conference at the National Institutes of Health. Annals of internal medicine. 1967 Feb:66(2):365-95
[PubMed PMID: 4163283]
[32]
Wanders RJA, Waterham HR, Ferdinandusse S. Peroxisomes and Their Central Role in Metabolic Interaction Networks in Humans. Sub-cellular biochemistry. 2018:89():345-365. doi: 10.1007/978-981-13-2233-4_15. Epub
[PubMed PMID: 30378031]